NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital leads EUR 132 million oversubscribed Series B financing in Azafaros to advance Phase 3 clinical programs of innovative therapies in rare inherited neuro-metabolic disorders
Proceeds will support two Phase 3 pivotal programs with nizubaglustat, lead asset in Niemann-Pick disease Type C disease and GM1/GM2 gangliosidoses, three forms of rare lysosomal storage disorders, as well as expanding Azafaros pipeline to other indications The...
Download our White Paper
We are pleased to share with you our White Paper, which offers a deep dive into the evolving biopharma landscape and highlights the key trends shaping its future.
Find all our press releases
Jeito Capital creates a community of leading international Special Advisors to complement its extensive sets of skills and further extend its support to portfolio companies
Paris, France, November 29th 2023 - Jeito Capital (“Jeito”), a leading global investment company...
Jeito Capital leads €75 million Series B Financing in NMD Pharma, a Danish company, to develop breakthrough treatments for patients with severe neuromuscular diseases
Jeito Capital’s second round of funding will support NMD Pharma in becoming a leading, global,...
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
EyeBio doubles the size of its original Series A raise with an additional $65 million, with new...
Jeito Capital renewed in “TIBI 2”
Paris, France, September 11th 2023 - Three years after being the 1st biopharma fund to be awarded...
Jeito Capital co-leads EUR 65 million (USD 71 million) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases
Jeito Capital co-leads oversubscribed financing Corteria, a late preclinical stage company, is...
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for Claudin-1 in cancer & fibrosis
Funds will support the Phase I/II clinical development of Alentis’ two first-in-class...
Face to face
Meet Jeito
16-17
December
All day long
Conference of Paris 2024
Jeito will be present at the Conference of Paris 2024, for its 8th edition around the theme “Confronting the Unknown”, encouraging leaders to share their knowledge and understanding of global economic, social and environmental issues as a way to collaborate and collectively overcome these challenges.
13-16
January
All day long
JPM Healthcare Conference 2025
Jeito will be present at the 43rd JPM Healthcare Conference 2025, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.
28-30
January
All day long
IPEM Cannes 2025
Jeito will be present at the 11th edition of IPEM Cannes – Wealth 2025, gathering Private Capital key decision-makers and incubating this year “IPEM Wealth”, a brand-new format designed to support the democratization of Private Markets, in Cannes.